The FDA decision is a binary event, and it can make or mar a company's stock depending on the outcome. Some drugs pass the regulatory muster on their first attempt, while some drugs face a long and labyrinthine regulatory process.
The company we are profiling today belongs to the latter category: Outlook Therapeutics Inc. (OTLK). Its investigational product in the U.S., Lytenava, proposed for the treatment of wet AMD, has been thrice rejected by the FDA. Nevertheless, the company continues to exude a steely determination to bring the drug to the U.S. market and has been working toward it.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.